Behavior and outcomes of 141 acquired lacrimal sac mucoceles treated via endoscopic dacryocystorhinostomy

141例经内镜下鼻泪管切开术治疗的后天性泪囊黏液囊肿的行为和结果

阅读:1

Abstract

AIM: To investigate the clinical profile of patients with acquired lacrimal sac mucocele (ALSM) and evaluate the efficacy of endoscopic dacryocystorhinostomy (En-DCR) for this condition. METHODS: En-DCRs were performed on 141 patients with ALSM patients from January 2016 to March 2022. The clinical baseline information and magnetic resonance imaging (MRI) images were recorded and summarized. To assess the effectiveness of En-DCR therapy, both anatomical and functional success rate was assessed during a 12mo follow-up. RESULTS: A total of 141 patients, with a mean age of 57.70±14.11y, were enrolled in this study. Majority of the patients were female (n=91; 64.54%) and all had unilateral disease. All patients had a previous history of epiphora and purulent secretion, and the duration from lacrimal duct obstruction to mucocele formation ranged from 6 to 120mo. MRI findings consistently revealed an enlarged sac diameter, fluid accumulation separated by a thin rim from adjacent tissues, which is indicative of lacrimal sac mucocele. En-DCR was performed with an anatomical success rate of 93.62% and a functional success rate of 81.56%. CONCLUSION: ALSM is more commonly seen in females and unilaterally. It is essentially a complication of lacrimal duct obstruction. MRI characteristics can be used for precise clinical diagnosis, while En-DCR emerges as an optimal therapy for this condition. Our results provide a comprehensive reference for the diagnosis and treatment of ALSM.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。